(thirdQuint)Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis.

 This is a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis.

 Approximately 160 subjects aged 6 years to 50 kg).

 The study consists of 5 periods: screening (up to 4 weeks), induction (of 12 weeks), maintenance (of 40 weeks), extension treatment epoch (open-label of 184 weeks) and post- treatment follow-up epoch (of 16 weeks).

 The primary objectiove of the study is to demonstrate the superiority of secukinumab (low and high dose) in pediatric subjects with severe chronic plaque psoriasis with respect to both PASI 75 and IGA mod 2011 0 or 1 response (co-primary endpoints) at Week 12, compared to placebo.

 Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis@highlight

This is a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis.

 Approximately 160 subjects aged 6 years to <18 years will be enrolled, of which at least 30 will be 6 years to <12 years old.

 It is expected that subjects will be enrolled at approximately 70 study sites worldwide.

